Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
PSTI develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases.
PSTI also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS.
PSTI has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; and a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication.
Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
July 19, 2019
RegMed Investors’ (RMi) closing bell: expiration of options amplified the sector’s selloff
June 29, 2019
RegMed Investors’ (RMi) closing bell: it’s over …
June 28, 2019
RegMed Investors’ (RMi) pre-open: just end it on a positive note
June 27, 2019
RegMed Investors’ (RMi) closing bell: the expectation occurs after halting a sector slide
June 27, 2019
RegMed Investors’ (RMi) pre-open: hoping for a trade deal
June 26, 2019
RegMed Investors’ (RMi) closing bell: some revival, into another bottom the sector fell, even curbing my expectation
June 24, 2019
RegMed Investors’ (RMi) closing bell: slipping and sliding
June 21, 2019
RegMed Investors’ (RMi) closing bell: the week pivoted to a positive session
June 20, 2019
RegMed Investors’ (RMi) closing bell: the problem today was the sector folded with machines stuffing the tickets
45 companies, 1 interpreter!
Insight, foresight and recommendation
Pluristem (PSTI) – Opened 2018 at $1.44, saw a high of $1.61 and started 2/1 at $1.47 with 2/21 having slipped to $1.38. News is always an appreciator that is never followed through ... PSTI needs to refine its communication to shareholders and operates on assumptions. With $36M of cash on hand and pivotal studies (three) being paid for by grants, estimates assume a quarterly cash burn rate of $8M – I am still a critic expecting data readouts from three of its clinical programs in 2018. Traders "play" the shares - too often ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors
© 2019 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.